董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeremy Curnock Cook | 男 | Independent Director | 74 | 11.22万美元 | 未持股 | 2025-10-16 |
| Jan Stern Reed | 女 | Lead Independent Director | 65 | 25.82万美元 | 未持股 | 2025-10-16 |
| Suzanne Crowe | 女 | Independent Director | 73 | 11.86万美元 | 未持股 | 2025-10-16 |
| Michael Tarnoff | 男 | Director | -- | 未披露 | 未持股 | 2025-10-16 |
| Cary Vance | -- | Chairman of the Board, Interim Chief Executive Officer | -- | 未披露 | 未持股 | 2025-10-16 |
| Robert E. Mcnamara | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cary Vance | -- | Chairman of the Board, Interim Chief Executive Officer | -- | 未披露 | 未持股 | 2025-10-16 |
| Nicole Kelsey | -- | Chief Legal Officer and Chief Compliance Officer and Corporate Secretary | -- | 未披露 | 未持股 | 2025-10-16 |
| David O'Toole | -- | Chief Financial Officer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2025-10-16 |
董事简历
中英对照 | 中文 | 英文- Jeremy Curnock Cook
-
Jeremy Curnock Cook自1995年7月以来担任董事会成员，自1998年2月以来担任董事长。从2014年9月到2015年5月他担任公司的临时首席执行官。他将辞去临时首席执行官的职务，于2015年5月18日生效，但将继续担任董事长。他自2000年以来担任International Bioscience Managers Limited（企业和投资咨询公司）的主席，担任Bioscience Managers Pty Ltd（医学科学基金经营商）的董事总经理。他从1987年到2000年担任Rothschild Asset Management Limited（企业和投资咨询公司）的董事，负责Rothschild生物科学单元。他于1975年创立the International Biochemicals Group（国际生化药剂集团），在1985年出售给Royal Dutch Shell，在那里他担任执行董事直到1987年。他持有都柏林Trinity College的自然科学硕士学位。他还担任Avita Medical Ltd, Nexus6 Ltd和SeaDragon Ltd的董事会成员。
Jeremy Curnock Cook has served as a Non-Executive Director since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years.Over his career, Mr. Curnock Cook has successfully managed in excess of US $1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia. In addition to serving on Avita Medical, Inc. Board of Directors, Jeremy currently serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics Pty Ltd appointed February 2012, Sea Dragon appointed October 2012, Smart Matrix Ltd appointed February 2013, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, CriL appointed November 2020, and Humanetix Ltd appointed September 2021. - Jeremy Curnock Cook自1995年7月以来担任董事会成员，自1998年2月以来担任董事长。从2014年9月到2015年5月他担任公司的临时首席执行官。他将辞去临时首席执行官的职务，于2015年5月18日生效，但将继续担任董事长。他自2000年以来担任International Bioscience Managers Limited（企业和投资咨询公司）的主席，担任Bioscience Managers Pty Ltd（医学科学基金经营商）的董事总经理。他从1987年到2000年担任Rothschild Asset Management Limited（企业和投资咨询公司）的董事，负责Rothschild生物科学单元。他于1975年创立the International Biochemicals Group（国际生化药剂集团），在1985年出售给Royal Dutch Shell，在那里他担任执行董事直到1987年。他持有都柏林Trinity College的自然科学硕士学位。他还担任Avita Medical Ltd, Nexus6 Ltd和SeaDragon Ltd的董事会成员。
- Jeremy Curnock Cook has served as a Non-Executive Director since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years.Over his career, Mr. Curnock Cook has successfully managed in excess of US $1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia. In addition to serving on Avita Medical, Inc. Board of Directors, Jeremy currently serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics Pty Ltd appointed February 2012, Sea Dragon appointed October 2012, Smart Matrix Ltd appointed February 2013, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, CriL appointed November 2020, and Humanetix Ltd appointed September 2021.
- Jan Stern Reed
-
Jan Reed最近担任沃尔格林联合博姿公司的高级副总裁，总法律顾问兼公司秘书，该公司是一家全球制药主导的健康和福利企业，年收入超过1150亿美元。在此之前，里德女士曾担任Solo Cup公司的人力资源执行Vice President、总法律顾问兼公司秘书，以及百特国际有限公司的副总法律顾问、公司秘书兼首席治理官。Reed女士在密歇根大学（University of Michigan）以优异成绩获得心理学文学学士学位，并在西北大学法学院（Northwestern University School of Law）获得法学博士学位。里德女士目前还担任Stepan Company公司（纽约证券交易所代码:SCL）的董事会成员。
Jan Stern Reed From 2013 to 2016, Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary (since 2015) at Walgreens Boots Alliance, Inc., a global pharmacy led, health and llbeing enterprise with annual revenues during her tenure in excess of $115 billion. Prior to this role, Ms. Reed served for seven years as Executive Vice President of Human Resces, General Counsel and Corporate Secretary at Solo Cup Company, and, prior thereto, as Associate General Counsel, Corporate Secretary and Chief Governance Officer at Baxter International Inc. Ms. Reed earned a Bachelor of Arts degree, with honors, in Psychology from the University of Michigan, and a Juris Doctor from Northstern University School of Law. Ms. Reed also currently serves as a member of the Board of Directors for Stepan Company (NYSE:SCL) and AVITA Medical, Inc. (Nasdaq:RCEL; ASX; AVH). Ms. Reed is a member of Audit Committee and is the Chair of the Nominating, Compliance and Corporate Governance Committee. - Jan Reed最近担任沃尔格林联合博姿公司的高级副总裁，总法律顾问兼公司秘书，该公司是一家全球制药主导的健康和福利企业，年收入超过1150亿美元。在此之前，里德女士曾担任Solo Cup公司的人力资源执行Vice President、总法律顾问兼公司秘书，以及百特国际有限公司的副总法律顾问、公司秘书兼首席治理官。Reed女士在密歇根大学（University of Michigan）以优异成绩获得心理学文学学士学位，并在西北大学法学院（Northwestern University School of Law）获得法学博士学位。里德女士目前还担任Stepan Company公司（纽约证券交易所代码:SCL）的董事会成员。
- Jan Stern Reed From 2013 to 2016, Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary (since 2015) at Walgreens Boots Alliance, Inc., a global pharmacy led, health and llbeing enterprise with annual revenues during her tenure in excess of $115 billion. Prior to this role, Ms. Reed served for seven years as Executive Vice President of Human Resces, General Counsel and Corporate Secretary at Solo Cup Company, and, prior thereto, as Associate General Counsel, Corporate Secretary and Chief Governance Officer at Baxter International Inc. Ms. Reed earned a Bachelor of Arts degree, with honors, in Psychology from the University of Michigan, and a Juris Doctor from Northstern University School of Law. Ms. Reed also currently serves as a member of the Board of Directors for Stepan Company (NYSE:SCL) and AVITA Medical, Inc. (Nasdaq:RCEL; ASX; AVH). Ms. Reed is a member of Audit Committee and is the Chair of the Nominating, Compliance and Corporate Governance Committee.
- Suzanne Crowe
-
Suzanne Crowe自2016年1月起担任非执行董事。Australian-based，她是一名医生科学家和公司董事，在支持公司的医疗和科学战略方面拥有丰富的专业知识。克罗教授是澳大利亚国家卫生和医学研究委员会的主要研究员。她是墨尔本阿尔弗雷德医院（the Alfred Hospital，Melbourne）传染病首席专家和墨尔本莫纳什大学（Monash University，Melbourne）医学和传染病兼职教授，并发表了200多篇同行评议论文。Crowe教授是澳大利亚公司董事协会的成员，也是澳大利亚最大的非营利性健康和老年护理提供商St Vincents Health Australia的董事。Crowe教授于2011年被任命为Australia AM勋章成员，以表彰她对艾滋病毒/艾滋病医学研究的服务。她拥有Monash University的医学和医学博士学位，the Royal Australasian College of Physicians的传染病内科专家资格，以及the Royal Melbourne Institute of Technology的医学实验室技术文凭。
Suzanne Crowe has served as a Non-Executive Director since January 2016. Australian-based, she is a physician-scientist with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, she is currently a Non-Executive Director of St Vincent's Health Australia Ltd, the country's largest not-for-profit health and aged care provider, and Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. She was appointed Emeritus Professor, Monash University, Melbourne in 2020. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and the university-affiliated Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education. She has medical and MD degrees from Monash University, an internal medicine specialist qualification in Infectious Diseases from the Royal Australasian College of Physicians, and a Diploma in Medical Laboratory Technology from the Royal Melbourne Institute of Technology. - Suzanne Crowe自2016年1月起担任非执行董事。Australian-based，她是一名医生科学家和公司董事，在支持公司的医疗和科学战略方面拥有丰富的专业知识。克罗教授是澳大利亚国家卫生和医学研究委员会的主要研究员。她是墨尔本阿尔弗雷德医院（the Alfred Hospital，Melbourne）传染病首席专家和墨尔本莫纳什大学（Monash University，Melbourne）医学和传染病兼职教授，并发表了200多篇同行评议论文。Crowe教授是澳大利亚公司董事协会的成员，也是澳大利亚最大的非营利性健康和老年护理提供商St Vincents Health Australia的董事。Crowe教授于2011年被任命为Australia AM勋章成员，以表彰她对艾滋病毒/艾滋病医学研究的服务。她拥有Monash University的医学和医学博士学位，the Royal Australasian College of Physicians的传染病内科专家资格，以及the Royal Melbourne Institute of Technology的医学实验室技术文凭。
- Suzanne Crowe has served as a Non-Executive Director since January 2016. Australian-based, she is a physician-scientist with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, she is currently a Non-Executive Director of St Vincent's Health Australia Ltd, the country's largest not-for-profit health and aged care provider, and Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. She was appointed Emeritus Professor, Monash University, Melbourne in 2020. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and the university-affiliated Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education. She has medical and MD degrees from Monash University, an internal medicine specialist qualification in Infectious Diseases from the Royal Australasian College of Physicians, and a Diploma in Medical Laboratory Technology from the Royal Melbourne Institute of Technology.
- Michael Tarnoff
-
迈克尔·塔诺夫（Michael Tarnoff），最近担任首席医师执行官兼首席执行官，任期至2024年。在塔夫茨大学担任多个领导职务期间，塔尔诺夫博士于2015年至2019年在美敦力公司担任首席医疗官兼医疗事务副总裁。在任职于美敦力之前，从2008年到2015年，Tarnoff博士在Covidien PLC担任公司首席医疗官兼医疗事务副总裁，在此之前，担任手术器械部门的首席医疗官兼医疗事务副总裁。其他行政领导经验包括2006年至2008年在GI Dynamics，Inc.担任医疗总监，以及2005年至2008年在Tyco Healthcare的Kendall手术部门担任首席医疗顾问。在获得圣路易斯华盛顿大学的文学学士学位后，塔尔诺夫博士获得了新泽西州医学和牙科大学的医学学位。随后，他在罗格斯医学院完成了普通外科住院医师，随后在克利夫兰诊所获得了腹腔镜手术高级研究金。
Michael Tarnoff,most recently as the Chief Physician Executive and CEO, until 2024. While serving in various leadership positions at Tufts, Dr. Tarnoff served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic, Inc. from 2015 to 2019. Before working for Medtronic, from 2008 through 2015, Dr. Tarnoff was the Corporate Chief Medical Officer and Vice President, Medical Affairs, and before that position, the Chief Medical Officer and Vice President, Medical Affairs of the Surgical Devices division, at Covidien plc. Additional executive leadership experience includes roles serving as Medical Director at GI Dynamics, Inc. from 2006 to 2008, as well as Chief Medical Consultant to the Kendall surgery unit of Tyco Healthcare from 2005 to 2008. After earning a Bachelor of Arts degree from Washington University in St. Louis, Dr. Tarnoff received his medical degree from the University of Medicine and Dentistry of New Jersey. He then completed a general surgery residency at Rutgers Medical School, followed by an advanced fellowship in laparoscopic surgery at the Cleveland Clinic. - 迈克尔·塔诺夫（Michael Tarnoff），最近担任首席医师执行官兼首席执行官，任期至2024年。在塔夫茨大学担任多个领导职务期间，塔尔诺夫博士于2015年至2019年在美敦力公司担任首席医疗官兼医疗事务副总裁。在任职于美敦力之前，从2008年到2015年，Tarnoff博士在Covidien PLC担任公司首席医疗官兼医疗事务副总裁，在此之前，担任手术器械部门的首席医疗官兼医疗事务副总裁。其他行政领导经验包括2006年至2008年在GI Dynamics，Inc.担任医疗总监，以及2005年至2008年在Tyco Healthcare的Kendall手术部门担任首席医疗顾问。在获得圣路易斯华盛顿大学的文学学士学位后，塔尔诺夫博士获得了新泽西州医学和牙科大学的医学学位。随后，他在罗格斯医学院完成了普通外科住院医师，随后在克利夫兰诊所获得了腹腔镜手术高级研究金。
- Michael Tarnoff,most recently as the Chief Physician Executive and CEO, until 2024. While serving in various leadership positions at Tufts, Dr. Tarnoff served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic, Inc. from 2015 to 2019. Before working for Medtronic, from 2008 through 2015, Dr. Tarnoff was the Corporate Chief Medical Officer and Vice President, Medical Affairs, and before that position, the Chief Medical Officer and Vice President, Medical Affairs of the Surgical Devices division, at Covidien plc. Additional executive leadership experience includes roles serving as Medical Director at GI Dynamics, Inc. from 2006 to 2008, as well as Chief Medical Consultant to the Kendall surgery unit of Tyco Healthcare from 2005 to 2008. After earning a Bachelor of Arts degree from Washington University in St. Louis, Dr. Tarnoff received his medical degree from the University of Medicine and Dentistry of New Jersey. He then completed a general surgery residency at Rutgers Medical School, followed by an advanced fellowship in laparoscopic surgery at the Cleveland Clinic.
- Cary Vance
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert E. Mcnamara
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Cary Vance
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Nicole Kelsey
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- David O'Toole
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介